FY2025 · ended Dec 31, 2025 · Revenue $49.80M, +60.2% YoY · Filed Mar 5, 2026
Lexicon Pharmaceuticals, Inc. (LXRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $49.8 million and a net loss of $50.3 million. Free cash flow was -$67.9 million. As of Jun 30, 2026 it held $190.6 million in cash and investments and $59.2 million in total debt.
Revenue (TTM)
$41.47M
-29.0% vs year-ago TTM
Net income (TTM)
$-61.12M
+49.3% vs year-ago TTM
Operating cash flow (TTM)
$-64.99M
+36.2% vs year-ago TTM
Free cash flow
$-67.85M
+62.3% vs prior year
EPS (TTM)
$-0.16
+53.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
423.68M
+17.2% vs prior year
Net cash
$131.37M
as of Jun 30, 2026
Operating margin
-131.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- The Woodlands, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1062822
- Former names
- LEXICON PHARMACEUTICALS, INC./DE (until Dec 5, 2014); LEXICON GENETICS INC/TX (until Apr 2, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2019 Dec 31, 2022 |
FY 2019 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $0 | $0 |
| Operating income | -$48.9M | -$197.1M | -$171.8M | -$100.8M | -$87.1M |
| Net income | -$50.3M | -$200.4M | -$177.1M | -$101.9M | -$87.8M |
| Diluted EPS | -$0.14 | -$0.63 | -$0.80 | — | -$0.60 |
| Operating cash flow | -$67.9M | -$178.8M | -$161.9M | -$88.9M | -$87.0M |
| Free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | -$88.2M |
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M |
| Stockholders' equity | $107.5M | $145.9M | $93.1M | $117.1M | $113.6M |
| Cash and investments | $96.2M | $238.0M | $170.0M | $138.4M | $86.7M |
| Total debt | $62.2M | $106.1M | $106.1M | $49.9M | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 1003 Lexicon Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.